WARSAW, Ind., Dec. 28, 2021 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 3:00 p.m. Eastern Time.
A live webcast of the presentation can be accessed via Zimmer Biomet’s Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
ZBH-Con
|
Media |
Investors |
|
|
Meredith Weissman |
Keri Mattox |
|
|
703-346-3127 |
215-275-2431 |
|
|
Ezgi Yagci |
||
|
617-549-2443 |
||
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301451049.html
SOURCE Zimmer Biomet Holdings, Inc.
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…